[
    [
        {
            "time": "",
            "original_text": "脉流科技向建平：心脑血管AI辅诊行业仍是蓝海，但发展是非线性的",
            "features": {
                "keywords": [
                    "脉流科技",
                    "心脑血管",
                    "AI辅诊",
                    "蓝海",
                    "非线性发展"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "人工智能"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "脉流科技向建平：心脑血管AI辅诊行业仍是蓝海，但发展是非线性的",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "和讯SGI公司|4年稳涨19倍的大牛股，毛利率比肩茅台的健帆生物将遭遇两大威胁？",
            "features": {
                "keywords": [
                    "和讯SGI",
                    "健帆生物",
                    "大牛股",
                    "毛利率",
                    "茅台",
                    "威胁"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "和讯SGI公司|4年稳涨19倍的大牛股，毛利率比肩茅台的健帆生物将遭遇两大威胁？",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "乐普医疗(300003)：1H2021业绩预览略超预期 等待创新器械发力",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "业绩预览",
                    "超预期",
                    "创新器械"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "乐普医疗(300003)：1H2021业绩预览略超预期 等待创新器械发力",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]